CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
| Revenue (TTM) | $13.39M |
| Gross Profit (TTM) | $-461.80M |
| EBITDA | $-513.17M |
| Operating Margin | -1128.00% |
| Return on Equity | -26.10% |
| Return on Assets | -14.20% |
| Revenue/Share (TTM) | $0.14 |
| Book Value | $18.07 |
| Price-to-Book | 2.96 |
| Price-to-Sales (TTM) | 386.64 |
| EV/Revenue | 327.03 |
| EV/EBITDA | 14.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1041.00% |
| Shares Outstanding | $96.69M |
| Float | $96.20M |
| % Insiders | 5.89% |
| % Institutions | 77.82% |
Volatility is currently contracting
CRISPR Therapeutics (CRSP) remains a "Strong Buy," supported by robust CASGEVY sales growth and pipeline expansion. CASGEVY achieved $76 million Q2 2026 sales, up 151% YoY, and now targets SCD and TDT patients as young as 2 years old. CTX310 demonstrated promising phase 1 results in lipid disorders, with key data updates expected at ESC Congress and in H2 2026.
CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are imminent. CASGEVY's efficacy and expanding market access, combined with a robust cash position, underpin a favorable risk/reward at current levels.
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.
Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CRSP and any ticker you trade — then tracks every position and per-strategy win rate.
